Found 113 clinical trials
A Double-Blind, Randomized controlled study of Etanercept and Methotrexate in combination or as Monotherapy in subjects with Psoriatic Arthritis
A Double-Blind, Randomized controlled study of Etanercept and Methotrexate in combination or as Monotherapy in subjects with Psoriatic Arthritis
- 451 views
- 23 Nov, 2020
- 1 location
A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis
Subjects With Active Psoriatic Arthritis
- 2412 views
- 23 Nov, 2020
- 18 locations
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Investigational Product in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Investigational Product in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy
- 789 views
- 08 Nov, 2020
- 1 location
Do you suffer from lower back pain?
Do you suffer from lower back pain?
- 1562 views
- 08 Nov, 2020
- 1 location
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX)
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
- 44 views
- 03 May, 2022
- 161 locations
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis (PEAPOD)
The study will aim to estimate the efficacy of apremilast compared with placebo in the treatment of juvenile psoriatic arthritis (JPsA) in pediatric participants 5 to less than 18 years of age
- 0 views
- 05 May, 2022
- 18 locations
Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis. (FOREMOST)
This clinical study will test the effects of a drug called apremilast in oligoarticular psoriatic arthritis with less than 5 years of disease duration. In previous studies, apremilast has been
- 371 views
- 25 Mar, 2022
- 103 locations
A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease (STAR)
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by assessing reduction in axial symptoms and
- 92 views
- 02 May, 2022
- 97 locations
A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis (AFFINITY)
The purpose of this study is to evaluate the efficacy of guselkumab plus golimumab combination treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) to a
- 5 views
- 02 May, 2022
- 27 locations
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent (SOLSTICE)
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) and/or intolerance to a prior
- 0 views
- 03 May, 2022
- 95 locations